BioMarin Pharmaceutical - רווחיות תפעולית BMRN

BioMarin Pharmaceutical is developing specialty pharmaceuticals through partnerships with clinics and laboratories, accelerating the launch of drugs for hereditary pathologies. The operating margin trend on GURU.Markets reflects business efficiency, with the value fixed at 19.20. Stable demand for gene therapy protects revenues and expands sales markets. The company's impeccable scientific image guarantees the full trust of physicians and patients.
BMRN (biomarin.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Operating margin measures cost management efficiency by determining the percentage of revenue remaining after covering all operating expenses before taxes and interest. For BioMarin Pharmaceutical (BMRN), the share of profit from core operations confirms strong pricing power within the rare disease niche, where lifelong therapy ensures stable cash flows, rendering the asset resilient to market downturns.